

Performance Against Initiation Benchmark

Count	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Date of First Patient Recruited	Reasons for delay correspond to:
1	16/LO/1502	178292	CTC-STOP	25/01/2018	23/04/2018	23/04/2018	23/04/2018	07/10/2016	28/09/2018		Neither
2	16/ES/0110	207747	TOPaZ study	13/01/2017	15/05/2018	15/05/2018	15/05/2018	12/01/2017	05/09/2018	22/01/2019	Both
3	17/SW/0201	180937	MiBRVO	01/01/2015	08/05/2018	08/05/2018	08/05/2018	06/04/2018	30/05/2018	12/12/2018	Neither
4	17/SW/0202	180940	MiCRVO	01/01/2015	08/05/2018	08/05/2018	08/05/2018	29/01/2018	30/05/2018		Neither
5	16/LO/2186	188540	IMAT-Neuroblastoma	27/10/2017	03/05/2018	03/05/2018	03/05/2018	17/01/2017	04/05/2018	14/05/2018	Benchmark Met
6	17/EM/0468	234972	A3921104 - Tofacitinib for treatment of Juvenile Idiopathic Arthritis	13/09/2017	04/04/2018	04/04/2018	04/04/2018	27/03/2018	26/04/2018		Neither
7	17/YH/0381	225986	GAP Study: Gabapentin in Post Surgery Pain	17/01/2018	04/04/2018	04/04/2018	04/04/2018	09/01/2018	12/04/2018	24/04/2018	Benchmark Met
8	17/LO/0933	220629	SAPPHIRE - A randomised study for participants with RVO	01/06/2017	09/04/2018	09/04/2018	09/04/2018	15/01/2018			Sponsor
9	16/SC/0526	208162	EYS606-CT1	07/09/2016	10/04/2018	10/04/2018	10/04/2018	05/06/2017	10/05/2018	06/06/2018	Benchmark Met
10	17/LO/1055	228923	Elective rituximab in TTP	11/12/2017	11/04/2018	11/04/2018	11/04/2018	31/07/2017	22/01/2019		Sponsor
11	17/EM/0355	229043	SPIRIT 2	18/08/2017	12/04/2018	12/04/2018	12/04/2018	10/11/2017	10/07/2018		Sponsor
12	17/NE/0151	223815	SGI-110 vs Treatment Choice in Adults with Previously Treated AML	24/08/2017	13/04/2018	13/04/2018	13/04/2018	19/07/2017	23/04/2018	23/04/2018	Benchmark Met
13	18/LO/0683	239811	YO40245 (IMBrave150) - Atezolizumab & Bevacizumab Vs. Sorafenib in HCC	22/01/2018	16/04/2018	16/04/2018	16/04/2018	13/06/2018	23/07/2018		Neither
14	18/EM/0015	235158	A3921145: A LONG-TERM, OPEN-LABEL FOLLOW-UP STUDY OF TOFACITINIB FOR TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS (JIA)	16/10/2017	17/04/2018	17/04/2018	17/04/2018	03/04/2018			Sponsor
15	16/EE/0324	203951	Prophylactic and Pre-emptive DLI for myeloid malignancies (PRO-DLI)	10/11/2017	30/04/2018	30/04/2018	30/04/2018	08/09/2016	30/04/2018	15/05/2018	Benchmark Met
16	17/EE/0368	213669	Study into the Reversal of Septic Shock with Landiolol (Beta Blockade)	16/04/2018	02/05/2018	02/05/2018	02/05/2018	10/11/2017	13/08/2018	02/10/2018	Sponsor
17	18/LO/0126	239586	Phase 1 study of WVE-210201 in patients with DMD	14/12/2017	02/05/2018	02/05/2018	02/05/2018	12/04/2018	08/08/2018	06/09/2018	Sponsor
18	18/EM/0027	235145	OPT-302 with ranibizumab for the treatment of wet AMD	15/09/2017	04/05/2018	04/05/2018	04/05/2018	28/02/2018	20/06/2018		Neither
19	17/LO/1711	234276	Synbiotic Extensively Hydrolysed Feed Study	14/02/2018	10/05/2018	10/05/2018	10/05/2018	24/10/2017	18/08/2018	18/10/2018	Sponsor
20	17/WS/0142	221370	PRIMUS 001	12/01/2018	01/06/2018	01/06/2018	01/06/2018	07/09/2017	05/09/2018	19/09/2018	Both
21	18/NW/0100	235042	BATCH Trial	09/03/2018	23/05/2018	23/05/2018	23/05/2018	13/04/2018	04/09/2018	05/09/2018	Sponsor
22	18/WA/0005	223997	"Best of" Radiotherapy vs "Best of" Surgery	03/04/2018	04/06/2018	04/06/2018	04/06/2018	12/03/2018	22/02/2019		Sponsor
23	17/WS/0147	184216	PrecisionPanc	06/02/2018	08/06/2018	08/06/2018	08/06/2018	05/01/2018	13/08/2018	20/09/2018	NHS Provider
24	17/SW/0221	232448	(CAIN457K2340) Secukinumab compared with GP2017 in Active AS	30/01/2018	20/06/2018	20/06/2018	20/06/2018	28/11/2017	23/10/2018	22/11/2018	Sponsor
25	18/EE/0176	236637	Daratumumab in paediatric and young adults with ALL/LL	20/02/2018	13/08/2018	13/08/2018	13/08/2018	13/08/2018	17/08/2018		Neither

Performance Against Initiation Benchmark

Count	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Date of First Patient Recruited	Reasons for delay correspond to:
26	18/LO/0439	240940	A Randomized, Double-Blind Phase 2/3 Study of Relatlimab Combined with Nivolumab versus Nivolumab in Participants with Previously Untreated Metastatic or Unresectable Melanoma - CA224047	14/03/2018	26/06/2018	26/06/2018	26/06/2018	26/06/2018	27/06/2018	03/07/2018	Benchmark Met
27	18/LO/0378	234232	PIONEER III	03/04/2017	28/06/2018	28/06/2018	28/06/2018	22/06/2018	20/09/2018	12/10/2018	Sponsor
28	18/NE/0108	242365	PP-001-1001	21/08/2017	10/07/2018	10/07/2018	10/07/2018	08/06/2018	25/07/2018		Neither
29	18/YH/0223	243476	Study to evaluate conjugate MenACYW vaccine in the UK infant schedule	14/06/2018	16/07/2018	16/07/2018	16/07/2018	09/07/2018	24/09/2018	10/10/2018	Sponsor
30	18/EM/0024	232898	PARC	22/01/2018	01/08/2018	01/08/2018	01/08/2018	03/05/2018	18/09/2018	23/09/2018	Benchmark Met
31	18/EM/0112	236871	ALL-RIC	26/03/2018	03/08/2018	03/08/2018	03/08/2018	12/06/2018	25/09/2018	26/02/2019	Neither
32	18/LO/0722	238635	A Phase 3 study of Ozanimod as induction therapy for Crohn's Disease	11/04/2018	15/08/2018	15/08/2018	15/08/2018	30/07/2018	01/02/2019		Sponsor
33	18/WM/0190	240027	Combi-Aplus: Dabrafenib + Trametinib in BRAF+ve Melanoma	25/05/2018	15/08/2018	15/08/2018	15/08/2018	09/08/2018	30/08/2018	11/09/2018	Benchmark Met
34	18/SW/0050	235126	A3921288 Phase 3B/4 Study of Tofacitinib in Subjects with UC	02/02/2018	31/08/2018	31/08/2018	31/08/2018	19/04/2018	15/10/2018	25/10/2018	Benchmark Met
35	18/LO/0650	244645	PKU Low Calorie Drink Study	10/04/2018	16/07/2018	16/07/2018	16/07/2018	21/06/2018			Sponsor
36	18/SW/0121	239039	Nutrition and physical activity intervention for families with FH	15/06/2018	23/07/2018	23/07/2018	23/07/2018	08/06/2018	16/08/2018	29/01/2019	Sponsor
37	18/NW/0476	246649	Involve-CAT	17/04/2018	10/09/2018	10/09/2018	10/09/2018	06/09/2018	27/09/2018	22/10/2018	Benchmark Met
38	18/SW/0102	233231	The effect of plasma proteins on tissue regeneration	04/06/2018	05/09/2018	05/09/2018	05/09/2018	13/07/2018	18/09/2018	07/10/2018	Benchmark Met
39	18/WS/0137	247036	VISION Study of 177Lu-PSMA-617 in the treatment of PSMA-Positive mCRPC	25/07/2018	01/10/2018	01/10/2018	01/10/2018	10/09/2018	26/10/2018	28/12/2018	NHS Provider
40	18/SC/0281	245538	AFTER study	11/09/2018	03/10/2018	03/10/2018	03/10/2018	02/07/2018	11/12/2018	13/12/2018	NHS Provider
41	18/LO/0723	244615	RPC01-3203:study of Ozanimod as Maintenance therapy for Crohns Disease	11/04/2018	12/10/2018	12/10/2018	12/10/2018	18/09/2018	13/03/2019		Sponsor
42	18/LO/1223	244752	RPC01-3204: Open Label Extension study of Ozanimod for Crohn's Disease	11/04/2018	12/10/2018	12/10/2018	12/10/2018	18/09/2018	13/03/2019		Sponsor
43	17/NE/0358	220871	My-CRA, Liquid 13 Cis Retinoic Acid	03/07/2018	15/10/2018	15/10/2018	15/10/2018	04/01/2018	19/10/2018	30/11/2018	Benchmark Met
44	17/SC/0661	227234	Cytosponge for post-chemoradiation surveillance of oesophageal cancer	15/06/2018	15/10/2018	15/10/2018	15/10/2018	23/01/2018	18/12/2018		Sponsor
45	16/WA/0156	204506	UK Mini Mitral	07/09/2018	19/10/2018	19/10/2018	19/10/2018	19/07/2016	06/12/2018	11/01/2019	Sponsor

Performance Against Initiation Benchmark

Count	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Date of First Patient Recruited	Reasons for delay correspond to:
46	17/LO/1590	229278	A Phase III, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) (SCH-900475) plus Chemotherapy (XP or FP) versus Placebo plus Chemotherapy (XP or FP) as Neoadjuvant/Adjuvant Treatment for Gastric or Gastroesophageal...	24/08/2018	24/10/2018	24/10/2018	24/10/2018	27/10/2017	10/01/2019		Neither
47	18/LO/1193	242628	ILUMIEN IV: OPTIMAL PCI	02/08/2018	26/10/2018	26/10/2018	26/10/2018	25/10/2018	11/12/2018	10/01/2019	Sponsor
48	18/LO/1311	248599	GR40398 EFFICACY AND SAFETY OF RO6867461 IN DMO PATIENTS (RHINE) v1	07/06/2018	26/10/2018	26/10/2018	26/10/2018	03/10/2018	09/11/2018		NHS Provider
49	18/EM/0228	248988	Anti-viral effect of PC786 on RSV infection in HSCT recipients	19/06/2018	31/10/2018	31/10/2018	31/10/2018	21/08/2018	21/11/2018	16/01/2019	Sponsor
50	18/SC/0472	234266	ProMPT-2	07/09/2018	06/11/2018	06/11/2018	06/11/2018	24/10/2018	11/01/2019	05/02/2019	Sponsor
51	17/NI/0096	225743	HOPE-1	11/10/2018	09/11/2018	09/11/2018	09/11/2018	14/07/2017	26/11/2018	15/01/2019	Benchmark Met
52	18/LO/0165	224726	POLEM	14/09/2018	15/11/2018	15/11/2018	15/11/2018	09/05/2018	28/02/2019		Both
53	18/SC/0358	230456	Interleukin-2 Therapy of Autoimmunity in Diabetes	07/08/2018	16/11/2018	16/11/2018	16/11/2018	13/08/2018	28/01/2019		Sponsor
54	18/LO/1238	245332	Open Label Extension study of WVE-210201 in patients with DMD	04/10/2018	14/01/2019	14/01/2019	14/01/2019	25/10/2018	07/03/2019		Neither
55	17/SS/0052	196827	Early valve surgery for severe asymptomatic aortic stenosis (EVoLVeD)	11/09/2018	27/11/2018	27/11/2018	27/11/2018	17/06/2017			Sponsor
56	17/SC/0536	216069	COPELIA	16/10/2018	29/11/2018	29/11/2018	29/11/2018	04/12/2017	18/01/2019	31/01/2019	Benchmark Met
57	18/EE/0373	249396	Breast Cancer Her 2	15/05/2018	17/01/2019	17/01/2019	17/01/2019	19/01/2019	08/03/2019		Sponsor
58	18/LO/1450	248611	Marigold Study 4407/0001 Marinus	18/10/2018	21/01/2019	21/01/2019	21/01/2019	07/12/2018	06/02/2019		Not yet 70 days
59	18/NW/0812	254035	CAIN457M2301 (SUNSHINE): Secukinumab in hidradenitis suppurativa	02/11/2018	21/01/2019	21/01/2019	21/01/2019	16/01/2019	22/02/2019		Not yet 70 days
60	18/SC/0243	240684	ORION-4	25/07/2018	04/02/2019	04/02/2019	04/02/2019	01/10/2018			Not yet 70 days
61	18/SC/0016	191852	Focus: A study to test a new treatment for dry AMD	19/02/2018	11/02/2019	11/02/2019	11/02/2019	23/04/2018	18/02/2019		Not yet 70 days
62	19/YH/0013	255993	Phase 3 - XL184 in Combination with Atezolizumab vs Sorafenib in HCC	11/12/2018	20/02/2019	20/02/2019	20/02/2019	15/02/2019			Not yet 70 days
63	19/EM/0003	251874	Phase 3 Study of Edasalonexent in Duchenne Muscular Dystrophy	21/12/2018	27/02/2019	27/02/2019	27/02/2019	20/02/2019			Not yet 70 days
64	18/NE/0312	245315	LTE Efficacy / Safety Study Of PF-04965842, w/wo T'cal Meds, in Subjs 12+ years with Mod to Sev AD	27/11/2018	19/03/2019	19/03/2019	19/03/2019	14/12/2018			Not yet 70 days
65	18/NW/0699	241427	TACE-3	14/01/2019	21/03/2019	21/03/2019	21/03/2019	21/03/2019			Not yet 70 days
66	18/EE/0378	248600	Conbercept in Neovascular Age-related Macular Degeneration	20/11/2018	21/03/2019	21/03/2019	21/03/2019	10/01/2019			Not yet 70 days
67	18/NE/0264	250542	TRACKER	05/02/2019	25/03/2019	25/03/2019	25/03/2019	27/09/2018	28/03/2019		Not yet 70 days
68	18/EE/0099	239606	CL3-95005-006 SOLSTICE	08/02/2019	25/03/2019	25/03/2019	25/03/2019	01/06/2018			Not yet 70 days

Performance Against Initiation Benchmark

Count	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Date of First Patient Recruited	Reasons for delay correspond to:
69	19/SC/0113	241916	Idera 2125-MEL-301	20/07/2017	26/03/2019	26/03/2019	26/03/2019				Not yet 70 days
70	18/WM/0324	246654	FORCE - Forearm fracture Recovery in Children Evaluation	11/10/2018	14/01/2019	14/01/2019	14/01/2019	16/11/2018	13/02/2019	14/02/2019	Benchmark Met
71	18/SC/0471	242624	Service-review and Feasibility Trial in Paediatric Weight Management	11/01/2019	21/01/2019	21/01/2019	21/01/2019	08/11/2018			Not yet 70 days
72	18/WS/0172	251636	1011712	25/09/2018	31/01/2019	31/01/2019	31/01/2019	03/01/2019	15/02/2019		Not yet 70 days
73	18/SC/0222	223737	NeoCLEAR	29/11/2018	06/02/2019	06/02/2019	06/02/2019	12/06/2018			Not yet 70 days